NCT04953949CompletedNot Applicable
First-in-Human Trial of the Safety and Performance of NU-MAX® (IEIK13) as a Hemostatic Agent in Intracranial Neurosurgery
3-D Matrix Europe SAS2 sites in 1 country80 target enrollmentStarted: August 6, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 80
- Locations
- 2
- Primary Endpoint
- % of bleedings reaching hemostasis within 3 minutes
Study Overview
Brief Summary
The objective of this clinical investigation is to determine the performance and safety profile of NU-MAX® when used as a topical hemostat for oozing bleedings encountered during intracranial procedures, in which control of bleeding by conventional hemostatic techniques is either ineffective or impractical.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have been informed on the nature of the clinical investigation and provided written informed consent, prior to initiation of any study activities.
- •Able and willing to comply with the clinical investigation follow-up schedule.
- •Male or female human subjects aged 18 years or older at time of enrollment.
- •Requiring hemostasis during elective intracranial procedures, in which the intradural space is accessed and where the control of bleeding by conventional hemostatic techniques is either ineffective or impractical.
- •NU-MAX® is used at least once intraoperatively.
Exclusion Criteria
- •Patients undergoing emergency craniotomy for traumatic lesions or patients undergoing surgery for primary intracranial hemorrhage.
- •Patients undergoing surgical procedures using a transsphenoidal approach.
- •Intraoperative use of a different topical chemical hemostatic agent prior to the use of NU-MAX® during the same procedure and on the same bleeding point or in the same resection cavity.
- •Patients with a coagulation disorder or medical treatment affecting coagulation or platelet function, unless corrected or stopped prior to surgery.
- •Pregnant patients or patients planning to become pregnant during the clinical investigation.
- •Patients with known allergies to any of the components of NU-MAX®.
- •Patients currently participating in, or having been recently exited from (within 30 days from enrollment in this clinical investigation), or planning to enroll in another clinical investigation that may impact participation or outcomes (at the discretion of the sponsor) of this clinical investigation.
- •Patients with a condition, disorder, or other factor that, in the investigator's opinion, would interfere with study participation.
- •Fever (body temperature >38.5°C) prior to surgery, on the day of the procedure.
- •Patients with a Nickel allergy
Outcomes
Primary Outcomes
% of bleedings reaching hemostasis within 3 minutes
Time Frame: Intraoperatively
The percentage of bleedings reaching hemostasis within 3 minutes will be measured intraoperatively after the use of NU-MAX® (with a maximum of 3 measurements of hemostasis by NU-MAX® application per subject).
Secondary Outcomes
- % of bleedings reaching hemostasis within 6 minutes(Intraoperatively)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
NitiNotes' EndoZip System for the Treatment of ObesityObesityNCT03472196Nitinotes Surgical Ltd.14
Recruiting
Unknown
TetraDERM for Scar ReductioScar ManagementSurgery - Other surgerySkin - Other skin conditionsACTRN12624000965505Tetratherix Technology Pty Ltd45
Not yet recruiting
Unknown
TetraDERM for Scar ReductioScar ManagementSurgery - Other surgerySkin - Other skin conditionsACTRN12624000549527Tetratherix Technology Pty Ltd8
Completed
Phase 2
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With SchizophreniaSchizophreniaNCT01323205Janssen Research & Development, LLC100
Completed
Phase 1
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470Diabetes MellitusNCT02302443Hanmi Pharmaceutical Company Limited100